Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia [3]

Blood

Volumn 110, Issue 3, 2007, Pages 1074-1075

  Van Der Bom, Johanna G ^a,b   Gouw, Samantha C ^c   Van Den Berg, H Marijke ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

DATA ANALYSIS; DRUG CHOICE; DRUG RESEARCH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEMOPHILIA A; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 34547937945     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-084889     Document Type: Letter

References (4)

1. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006;107:46-51.
2. Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007;13:149-155.
3. Gouw SC, van der Bom JG, Auerswald G, Escuriola EC, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109:4693-4697.
4. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648-4654.